Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Journal of Gastroenterology
Erschienen in: Journal of Gastroenterology 7/2019

Open Access 20.04.2019 | Review

Management of elderly ulcerative colitis in Japan

verfasst von: Masaaki Higashiyama, Akira Sugita, Kazutaka Koganei, Kenji Wanatabe, Yoko Yokoyama, Motoi Uchino, Masakazu Nagahori, Makoto Naganuma, Shigeki Bamba, Shingo Kato, Ken Takeuchi, Teppei Omori, Tomohisa Takagi, Satohiro Matsumoto, Mitsuo Nagasaka, Shintaro Sagami, Kazuya Kitamura, Takehiko Katsurada, Ken Sugimoto, Noritaka Takatsu, Masayuki Saruta, Toshiyuki Sakurai, Kazuhiro Watanabe, Shiro Nakamura, Yasuo Suzuki, Ryota Hokari

Erschienen in: Journal of Gastroenterology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Japan has the largest aging society, where many elderly people have intractable diseases including ulcerative colitis (UC). Along with the increasing total number of UC patients, the number of elderly UC patients has also been increasing and will continue to do so in the future. Although the clinical features and natural history of UC in the elderly have many similarities with UC in the non-elderly population, age-specific concerns including comorbidities, immunological dysfunction, and polypharmacy make the diagnosis and management of elderly UC challenging compared to UC in non-elderly patients. Based on increasing data related to elderly UC patients from Japan, as well as other countries, we reviewed the epidemiology, clinical course, differential diagnosis, management of comorbidities, surveillance, medical therapy, and surgery of UC in the elderly.
Literatur
1.
2.
3.
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–17 (no definition of elderly).CrossRefPubMed
4.
Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15:39–49 (no definition of elderly).CrossRefPubMed
5.
6.
Komoto S, Higashiyama M, Watanabe C, et al. Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: a nationwide survey data in Japan. J Gastroenterol Hepatol. 2018;33:1839–43 (elderly ≥ 65 y.o.).CrossRefPubMed
7.
Sturm A, Maaser C, Mendall M, et al. European Crohn’s and colitis organisation topical review on IBD in the elderly. J Crohn’s Colitis. 2017;11:263–73 (review, elderly ≥ 60 y.o.).CrossRef
8.
Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10:1224–36 (meta-analysis, elderly ≥ 50 y.o.).CrossRefPubMedPubMedCentral
9.
Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–53 (guideline).CrossRefPubMedPubMedCentral
10.
11.
Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39:459–77 (meta-analysis, elderly ≥ 60 y.o.).CrossRefPubMed
12.
Jeuring SF, van den Heuvel TR, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis. 2016;22:1425–34 (elderly ≥ 60 y.o.).CrossRefPubMed
13.
Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977–2008. J Crohns Colitis. 2011;5:5–13 (elderly ≥ 60 y.o.).CrossRefPubMed
14.
Kalkan IH, Dagli U, Oztas E, et al. Comparison of demographic and clinical characteristics of patients with early vs. adult vs. late onset ulcerative colitis. Eur J Intern Med. 2013;24:273–7 (elderly ≥ 60 y.o.).CrossRefPubMed
15.
Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32 (elderly ≥ 60 y.o.).CrossRefPubMed
16.
Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43 (elderly ≥ 60 y.o.).CrossRefPubMed
17.
Shi HY, Chan FK, Leung WK, et al. Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry. J Crohns Colitis. 2016;10:176–85 (elderly ≥ 60 y.o.)..CrossRefPubMed
18.
Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15 (elderly ≥ 65 y.o.).CrossRefPubMed
19.
Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5 (elderly ≥ 65 y.o.).CrossRefPubMed
20.
Almogy G, Sachar DB, Bodian CA, et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg. (Chicago IL 1960). 2001;136:1396–400 (elderly ≥ 65 y.o.).CrossRef
21.
Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9 (elderly ≥ 65 y.o.).CrossRefPubMed
22.
Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. Dig Dis Sci. 2013;58:1306–12 (elderly ≥ 60 y.o.).CrossRefPubMed
23.
Ouchi Y, Rakugi H, Arai H, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17:1045–7 (elderly ≥ 75 y.o.).CrossRefPubMed
24.
Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–61 (no definition of elderly).CrossRefPubMed
25.
Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–9 (no definition of elderly).CrossRefPubMed
26.
Ling KL, Ooi CJ, Luman W, et al. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 2002;35:144–8 (no definition of elderly).CrossRefPubMed
27.
Subasinghe D, Nawarathna NM, Samarasekera DN. Disease characteristics of inflammatory bowel disease (IBD): findings from a tertiary care centre in South Asia. J Gastrointest Surg. 2011;15:1562–7 (no definition of elderly).CrossRefPubMed
28.
Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27:1266–80 (review).CrossRefPubMed
29.
Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44:659–65 (no definition of elderly).CrossRefPubMed
30.
Takahashi H, Matsui T, Hisabe T, et al. Second peak in the distribution of age at onset of ulcerative colitis in relation to smoking cessation. J Gastroenterol Hepatol. 2014;29:1603–8 (elderly ≥ 50 y.o.).CrossRefPubMed
31.
Song EM, Lee HS, Park SH, et al. Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis. J Gastroenterol Hepatol. 2018;33:172–9 (elderly ≥ 60 y.o.).CrossRefPubMed
32.
Araki M, Shinzaki S, Yamada T, et al. Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease. J Gastroenterol. 2017;52:1149–57 (elderly > 40 y.o.).CrossRefPubMed
33.
Lee KS, Shin WG, Jang MK, et al. Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea? Dis Colon Rectum. 2006;49:1552–8 (no definition of elderly).CrossRefPubMed
34.
Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44:74–8 (no definition of elderly).CrossRefPubMed
35.
Ko JH, Peck KR, Lee WJ, et al. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. Clin Infect Dis. 2015;60:e20–6 (no definition of elderly).CrossRefPubMed
36.
Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res. 2014;12:5–11 (review).CrossRefPubMedPubMedCentral
37.
Sarin A, Safar B. Management of radiation proctitis. Gastroenterol Clin N Am. 2013;42:913–25 (review).CrossRef
38.
Yasuda Y, Urata Y, Tohnai R, et al. Immune-related colitis induced by the long-term use of nivolumab in a patient with non-small cell lung cancer. Intern Med. 2018;57:1269–72 (case report).CrossRefPubMed
39.
Yamauchi R, Araki T, Mitsuyama K, et al. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol. 2018;18:135 (case report).CrossRefPubMedPubMedCentral
40.
Okamoto R, Negi M, Tomii S, et al. Diagnosis and treatment of microscopic colitis. Clin J Gastroenterol. 2016;9:169–74 (review).CrossRefPubMed
41.
Umeno J, Esaki M, Nuki Y, et al. Letter: Lansoprazole consumption is more common in Japanese patients with collagenous colitis. Aliment Pharmacol Ther. 2013;38:208–9 (no definition of elderly).CrossRefPubMed
42.
Tadros M, Majumder S, Birk JW. A review of ischemic colitis: is our clinical recognition and management adequate? Expert Rev Gastroenterol Hepatol. 2013;7:605–13 (review).CrossRefPubMed
43.
Jani N, Finkelstein S, Blumberg D, et al. Segmental colitis associated with diverticulosis. Dig Dis Sci. 2002;47:1175–81 (review).CrossRefPubMed
44.
Tursi A, Elisei W, Giorgetti GM, et al. Segmental colitis associated with diverticulosis: a 5-year follow-up. Int J Colorectal Dis. 2012;27:179–85 (review).CrossRefPubMed
45.
Cassieri C, Brandimarte G, Elisei W, et al. How to differentiate segmental colitis associated with diverticulosis and inflammatory bowel diseases. J Clin Gastroenterol. 2016;50(Suppl 1):S36–8 (review).CrossRefPubMed
46.
Abid S, Khawaja A, Bhimani SA, et al. The clinical, endoscopic and histological spectrum of the solitary rectal ulcer syndrome: a single-center experience of 116 cases. BMC Gastroenterol. 2012;12:72 (no definition of elderly).CrossRefPubMedPubMedCentral
47.
Park HB, Park HC, Chung CY, et al. Coexistence of solitary rectal ulcer syndrome and ulcerative colitis: a case report and literature review. Intest Res. 2014;12:70–3 (case report).CrossRefPubMedPubMedCentral
48.
Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44:431–40 (elderly ≥ 50 y.o.).CrossRefPubMed
49.
50.
Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166–75 (elderly ≥ 65 y.o.).CrossRefPubMed
51.
Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–8 (no definition of elderly).CrossRefPubMed
52.
Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789–99 (meta-analysis).CrossRefPubMed
53.
Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46–55 (no definition of elderly).CrossRefPubMed
54.
Song EM, Kim N, Lee SH, et al. Clinical characteristics and long-term prognosis of elderly-onset Crohn’s disease. Scand J Gastroenterol. 2018;53:417–25 (elderly ≥ 60 y.o.).CrossRefPubMed
55.
Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36 (oldest group ≥ 50 y.o.).CrossRefPubMed
56.
Bewtra M, Newcomb CW, Wu Q, et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med. 2015;163:262–70 (elderly ≥ 50 y.o.).CrossRefPubMedPubMedCentral
57.
Naganuma M, Kunisaki R, Yoshimura N, et al. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol. 2013;48:595–600 (oldest group ≥ 50 y.o.).CrossRefPubMed
58.
Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337–46 (elderly ≥ 65 y.o.).CrossRefPubMed
59.
Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–68 (consensus).CrossRefPubMed
60.
Naganuma M, Nagahori M, Fujii T, et al. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013;19:418–22 (no definition of elderly).CrossRefPubMed
61.
Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8 (guideline).CrossRefPubMed
62.
Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–65 (elderly ≥ 65 y.o.).CrossRefPubMedPubMedCentral
63.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32 (elderly ≥ 70 y.o.).CrossRefPubMed
64.
Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8:223–33 (oldest group ≥ 49 y.o.).CrossRefPubMed
65.
Matsumoto H, Ohfuji S, Watanabe K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. J Gastroenterol. 2015;50:876–86 (no definition of elderly).CrossRefPubMed
66.
Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152:1975–84 (no definition of elderly).CrossRefPubMedPubMedCentral
67.
Kaplan GG, Hubbard J, Panaccione R, et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64 (meta-analysis).CrossRefPubMed
68.
Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7:107–12 (elderly > 65 y.o.).CrossRefPubMed
69.
Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1795–802 (elderly ≥ 66 y.o.).CrossRefPubMed
70.
Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105:2040–9 (no definition of elderly).CrossRefPubMed
71.
Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–50 (no definition of elderly).CrossRefPubMed
72.
Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483–90 (elderly ≥ 65 y.o.).CrossRefPubMed
73.
Tsai SY, Yang TY, Lin CL, et al. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69:228–34 (elderly ≥ 65 y.o.).CrossRefPubMed
74.
Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age. Adv Ther. 2017;34:542–59 (elderly ≥ 55 y.o.).CrossRefPubMedPubMedCentral
75.
Kishikawa J, Hata K, Kazama S, et al. Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc. 2018;30:236–44 (no definition of elderly).CrossRefPubMed
76.
77.
Tran AH, Man Ngor EW, Wu BU. Surveillance colonoscopy in elderly patients: a retrospective cohort study. JAMA Intern Med. 2014;174:1675–82 (elderly ≥ 75 y.o.).CrossRefPubMed
78.
Stepaniuk P, Bernstein CN, Targownik LE, et al. Characterization of inflammatory bowel disease in elderly patients: a review of epidemiology, current practices and outcomes of current management strategies. Can J Gastroenterol Hepatol. 2015;29:327–33 (review).CrossRefPubMedPubMedCentral
79.
80.
Baggenstos BR, Hanson BJ, Shaukat A. Treatment of ulcerative colitis in the elderly: a systematic review. Clin Med Insights Geriatr. 2013;6:1–26 (elderly ≥ 60 y.o.).CrossRef
81.
Ananthakrishnan AN, Donaldson T, Lasch K, et al. Management of inflammatory bowel disease in the elderly patient: challenges and opportunities. Inflamm Bowel Dis. 2017;23:882–93 (review).CrossRefPubMedPubMedCentral
82.
Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441–51 (elderly ≥ 65 y.o.).CrossRefPubMed
83.
Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309–15 (elderly > 60 y.o.).CrossRefPubMedPubMedCentral
84.
Ito A, Omori T, Hanafusa N, et al. Efficacy and safety of granulocyte adsorption apheresis in elderly patients with ulcerative colitis. J Clin Apheresis. 2018;33:514–20 (elderly ≥ 65 y.o.).CrossRefPubMed
85.
Yamamoto T, Iida T, Ikeya K, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170 (elderly > 60 y.o.).CrossRefPubMedPubMedCentral
86.
Kawamura H, Matsumoto S, Nakamura N, et al. Rapid induction therapy with oral tacrolimus in elderly patients with refractory ulcerative colitis can easily lead to elevated tacrolimus concentrations in blood: a report of 5 cases. Am J Case Rep. 2017;18:405–9 (elderly ≥ 65 y.o.).CrossRefPubMedPubMedCentral
87.
Kobayashi R, Matsumoto S, Yoshida Y. Tacrolimus therapy for three patients with elderly-onset ulcerative colitis: report of three cases. Case Rep Gastroenterol. 2016;10:392–8 (elderly ≥ 60 y.o.).CrossRefPubMedPubMedCentral
88.
89.
Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy of inflammatory bowel disease in the elderly—prospects and complications. J Crohns Colitis. 2011;5:177–88 (review, elderly ≥ 65 y.o.).CrossRefPubMed
90.
Long MD, Kappelman MD, Martin CF, et al. Risk factors for depression in the elderly inflammatory bowel disease population. J Crohns Colitis. 2014;8:113–9 (elderly ≥ 65 y.o.).CrossRefPubMed
91.
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106 (review).CrossRefPubMed
92.
93.
Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97 (review).CrossRefPubMed
94.
Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49:656–64 (no definition of elderly).CrossRefPubMedPubMedCentral
95.
Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol. 1997;92:461–4 (meta-analysis, elderly ≥ 50 y.o.).PubMed
96.
Vinod J, Vadada D, Korelitz BI, et al. The effect of antiplatelet therapy in patients with inflammatory bowel disease. J Clin Gastroenterol. 2012;46:527–9 (no definition of elderly).CrossRefPubMed
97.
Danese S, De La Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004;99:938–45 (review).CrossRefPubMed
98.
Tan VP, Chung A, Yan BP, et al. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1095–113 (meta-analysis).CrossRefPubMed
99.
Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;(5):CD000478 (meta-analysis).
100.
Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740–6 (no definition of elderly).CrossRefPubMed
101.
Alexakis C, Saxena S, Chhaya V, et al. Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? A 20-year national population-based cohort study. Inflamm Bowel Dis. 2017;23:672–80 (elderly > 60 y.o.).CrossRefPubMed
102.
Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400 (elderly ≥ 65 y.o.).CrossRefPubMed
103.
Manosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case–control study. Aliment Pharmacol Ther. 2018;47:605–14 (elderly ≥ 60 y.o.).CrossRefPubMed
104.
Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:1070–5 (no definition of elderly).CrossRefPubMed
105.
Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5 (oldest group ≥ 70 y.o.).CrossRefPubMedPubMedCentral
106.
Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25 (elderly > 65 y.o.).CrossRefPubMed
107.
Subramaniam K, D’Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28:24–30 (review).CrossRefPubMed
108.
Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58 (meta-analysis, oldest group ≥ 70 y.o.).CrossRefPubMed
109.
Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86 (oldest group ≥ 65 y.o.).CrossRefPubMedPubMedCentral
110.
Fukata N, Okazaki K, Omiya M, et al. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol. 2014;49:1299–306 (no definition of elderly).CrossRefPubMed
111.
Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–99 (no definition of elderly).CrossRef
112.
Moran GW, Lim AW, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1002–24 (review).CrossRefPubMed
113.
Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256–65 (no definition of elderly).CrossRefPubMed
114.
Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab. 2002;3:275–87 (review).CrossRefPubMed
115.
Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford). 2006;45:441–4 (elderly ≥ 65 y.o.).CrossRefPubMed
116.
Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–84 (review).CrossRefPubMed
117.
Komaki Y, Komaki F, Ido A, et al. Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J Crohns Colitis. 2016;10:484–94 (meta-analysis).CrossRefPubMed
118.
Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up. Am J Gastroenterol. 2006;101:1048–56 (no definition of elderly).CrossRefPubMed
119.
Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis—a need for prophylaxis. J Crohns Colitis. 2010;4:606–9 (no definition of elderly).CrossRefPubMed
120.
Taleban S, Colombel JF, Mohler MJ, et al. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507–15 (review, elderly ≥ 60 y.o.).CrossRefPubMed
121.
Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19:355–63 (review).CrossRefPubMed
122.
Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:878–89 (elderly ≥ 65 y.o.).CrossRefPubMed
123.
Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol. 1997;92:1424–8 (guideline).PubMed
124.
Staatz CE, Tett SE. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs Aging. 2005;22:541–57 (review).CrossRefPubMed
125.
Gentil MA, Osuna A, Capdevila L, et al. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. Transplant Proc. 2003;35:1706–8 (elderly > 50 y.o.).CrossRefPubMed
126.
Takeuchi T, Kawai S, Yamamoto K, et al. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:8–16 (elderly ≥ 65 y.o.).CrossRefPubMed
127.
Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47–91 (review).CrossRefPubMed
128.
Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854–62 (oldest group ≥ 60 y.o.).CrossRefPubMed
129.
Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080–7 (no definition of elderly).CrossRefPubMed
130.
Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–8 (elderly ≥ 60 y.o.)..CrossRefPubMed
131.
Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19–31 (no definition of elderly).CrossRefPubMed
132.
Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50:1040–50 (review).CrossRefPubMed
133.
Komoto S, Matsuoka K, Kobayashi T, et al. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients. J Gastroenterol Hepatol. 2018;33:1485–91 (elderly ≥ 65 y.o.).CrossRefPubMed
134.
Futatsuki R, Kuroki H, Sugita A, et al. Clinical analysis of the postoperative bowel function in elderly patients with ulcerative colitis. Jpn J Gastroenterol Surg. 2016;49:714–20 (elderly ≥ 65 y.o.).CrossRef
135.
Sugita A, Koganei K, Tatsumi K, et al. Recent advances in medical and surgical treatment of ulcerative colitis. Nihon Geka Gakkai zasshi. 2015;116:99–103 (no definition of elderly).PubMed
136.
137.
Delaney CP, Dadvand B, Remzi FH, et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum. 2002;45:890–4 (elderly ≥ 70 y.o.).CrossRefPubMed
138.
Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238:221–8 (oldest group > 65 y.o.).PubMedPubMedCentral
139.
Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch Surg. 2005;140:534–9 (oldest group > 55 y.o.).CrossRefPubMed
140.
Watanabe K, Nagao M, Suzuki H, et al. The functional outcome and factors influencing the quality of life after ileal pouch anal anastomosis in patients with ulcerative colitis. Surg Today. 2018;48:455–61 (older group ≥ 45 y.o.).CrossRefPubMed
141.
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–70 (consensus).CrossRefPubMed
142.
Dayton MT, Larsen KR. Should older patients undergo ileal pouch-anal anastomosis? Am J Surg. 1996;172:444–7 (older group > 55 y.o.).CrossRefPubMed
143.
Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003;186:514–8 (oldest group ≥ 70 y.o.).CrossRefPubMed
144.
145.
McKenna NP, Mathis KL, Pemberton JH, et al. The impact of age at time of ileal pouch anal anastomosis on short and long-term outcomes in adults. Inflamm Bowel Dis. 2018;24:1857–65 (older group > 50 y.o.).CrossRefPubMed
146.
Ramage L, Qiu S, Georgiou P, et al. Functional outcomes following ileal pouch-anal anastomosis (IPAA) in older patients: a systematic review. Int J Colorectal Dis. 2016;31:481–92 (meta-analysis, elderly ≥ 65 ± 5 y.o.).CrossRefPubMedPubMedCentral
147.
Lightner AL, Mathis KL, Dozois EJ, et al. Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm Bowel Dis. 2017;23:781–90 (elderly ≥ 65 y.o.).CrossRefPubMed
148.
Tan KK, Manoharan R, Rajendran S, et al. Assessment of age in ulcerative colitis patients with ileal pouch creation—an evaluation of outcomes. Ann Acad Med Singap. 2015;44:92–7 (older group > 50 y.o.).PubMed
149.
Kim H, Sun L, Gurland B, et al. Does stool leakage increase in aging pouches? Dis Colon Rectum. 2015;58:1158–63 (no definition of elderly).CrossRefPubMed
150.
Stryker SJ, Pemberton JH, Zinsmeister AR. Long-term results of ileostomy in older patients. Dis Colon Rectum. 1985;28:844–6 (elderly ≥ 60 y.o.).CrossRefPubMed
Metadaten
Titel
Management of elderly ulcerative colitis in Japan
verfasst von
Masaaki Higashiyama
Akira Sugita
Kazutaka Koganei
Kenji Wanatabe
Yoko Yokoyama
Motoi Uchino
Masakazu Nagahori
Makoto Naganuma
Shigeki Bamba
Shingo Kato
Ken Takeuchi
Teppei Omori
Tomohisa Takagi
Satohiro Matsumoto
Mitsuo Nagasaka
Shintaro Sagami
Kazuya Kitamura
Takehiko Katsurada
Ken Sugimoto
Noritaka Takatsu
Masayuki Saruta
Toshiyuki Sakurai
Kazuhiro Watanabe
Shiro Nakamura
Yasuo Suzuki
Ryota Hokari
Publikationsdatum
20.04.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 7/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01580-y

Weitere Artikel der Ausgabe 7/2019

Journal of Gastroenterology 7/2019 Zur Ausgabe

Original Article—Liver, Pancreas, and Biliary Tract

Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience

Original Article—Liver, Pancreas, and Biliary Tract

Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

Original Article—Alimentary Tract

Feasibility of a simplified narrow-band imaging classification system for Barrett’s esophagus for novice endoscopists

Original Article—Liver, Pancreas, and Biliary Tract

Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis

Original Article—Alimentary Tract

Epidemiological analysis of achalasia in Japan using a large-scale claims database

Original Article—Alimentary Tract

Marked impact of tumor location on the appropriate cutoff values and the prognostic significance of the lymph node ratio in stage III colon cancer: a multi-institutional retrospective analysis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise